Protocol Ledger

NCT06121375 · Phase II/III · TERMINATED

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Interventional Phase II/III clinical trial protocol NCT06121375 sponsored by Intercept Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-02 Enrollment: 28 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06121375
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)28 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06121375
Protocol FieldVerified Registry Value
NCT IdentifierNCT06121375
Consolidated Lead SponsorIntercept Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment28 participants (ACTUAL)
Registered Start Date2024-09-02
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06121375
Hospital Research SiteLocationSite Profile
Queen Mary HospitalHong Kong, Hong KongOpen Hospital Dossier ->
Hadassah Medical CenterJerusalem, IsraelOpen Hospital Dossier ->
Shaare Zedek Medical CenterJerusalem, IsraelOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI